Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule Verrica Pharmaceuticals, a dermatology
Phase 3 Top Line Results Expected Q2 2026 Lipocine Inc, a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral
Bio-Thera Solutions , a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced that dosing has begun in a phase 3 clinical study
VSee Health a leading provider of HIPAA-compliant digital health solutions has been selected to support a NIH-funded Phase 3 clinical trial study on stroke recovery telerehabilitation based
Fuel up with free Health Tech Insights
